Most cited papers from SGS (Belgium)

SGS (Belgium)

What are the most cited papers from SGS (Belgium)?

The most cited paper from SGS (Belgium) is "A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran" (Viktoria Moschetti, Stephen H. Norris, Joachim Stangier et al., 2015), with 245 citations. Next come "Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor" (168) and "Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects" (118).

Published TypeFieldAccessCitations

Showing 50 of 50 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran Viktoria Moschetti, Stephen H. Norris, Joachim Stangier et al. · Thrombosis and Haemostasis	19 Mar 2015	245
2	Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor Douglas G. Johns et al. · Circulation Open access	May 2023	168
3	Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects Steven Ramael, Florence De Smedt, Nathalie Toublanc et al. · Clinical Therapeutics	May 2006	118
4	Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers Andi Leubitz, Anat Frydman‐Marom, Neal Sharpe et al. · Clinical Pharmacology in Drug Development Open access	16 Jan 2019	72
5	Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects Christopher John Wynne, Mario Altendorfer, Ivo Sonderegger et al. · Expert Opinion on Investigational Drugs Open access	4 Nov 2016	59
6	Revamping corrosion damaged reinforced concrete balconies: Life cycle assessment and life cycle cost of life-extending repair methods Lydia Wittocx, Matthias Buyle, Amaryllis Audenaert et al. · Journal of Building Engineering	27 Mar 2022	58
7	Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study Frédéric P. Vanhoutte, Liang Su, Marcella K. Ruddy et al. · The Journal of Clinical Pharmacology Open access	18 Jun 2020	55
8	Human challenge trials in vaccine development, Rockville, MD, USA, September 28–30, 2017 Marc F.D. Baay, Thomas L. Richie, Pieter Neels et al. · Biologicals	21 Mar 2018	51
9	Transportation Risk ANalysis tool for hazardous Substances (TRANS) – A user-friendly, semi-quantitative multi-mode hazmat transport route safety risk estimation methodology for Flanders Genserik Reniers, Katleen De Jongh, Bob Gorrens et al. · Transportation Research Part D Transport and Environment Open access	3 Aug 2010	46
10	Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies Holger Rosenbrock, Michael P. Desch, Oliver Kleiner et al. · Clinical and Translational Science Open access	23 Aug 2018	45
11	Recommendations on The Interpretation of The New European Medicines Agency Guideline on Bioanalytical Method Validation By Global Cro Council For Bioanalysis (Gcc) Mark Boterman et al. · Bioanalysis	Mar 2012	45
12	Clinical pharmacology of exogenously administered alkaline phosphatase Peter Pickkers, Ferdinand T. F. Snellen, Peter Rogiers et al. · European Journal of Clinical Pharmacology Open access	Dec 2008	41
13	A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects Andi Leubitz, Frédéric P. Vanhoutte, Ming‐yi Hu et al. · Clinical Pharmacology in Drug Development Open access	19 Jan 2021	36
14	Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers Michael Schmohl, Stephan Glund, Akiko Harada et al. · Thrombosis and Haemostasis	Dec 2016	36
15	Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study Odile Launay et al. · EBioMedicine Open access	2022	33
16	Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans Jeannette M. Watson, James N. Francis, Sofie Mesens et al. · Virology Journal Open access	2 Feb 2015	33
17	Recommendations on Bioanalytical Method Stability Implications of Co-Administered And Co-Formulated Drugs By Global Cro Council For Bioanalysis (Gcc) Steve Lowes et al. · Bioanalysis	Sep 2012	33
18	Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study Mohamed Farouk Chughlay, Myriam El Gaaloul, Cristina Donini et al. · American Journal of Tropical Medicine and Hygiene Open access	8 Feb 2021	32
19	Conference Report: The 3rd Global CRO Council for Bioanalysis at The International Reid Bioanalytical Forum Massimo Breda et al. · Bioanalysis	Dec 2011	32
20	First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects Linda L. Neuman, Renee Ward, David Arnold et al. · Blood	2 Dec 2016	30
21	A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers Katja Boland, Viktoria Moschetti, Chantaratsamon Dansirikul et al. · Human Psychopharmacology Clinical and Experimental	2017	29
22	Dialysability of Gadoteric Acid in Patients With End-Stage Renal Disease Undergoing Hemodialysis Eric E. O. Gheuens, Ronald Daelemans, Sofie Mesens · Investigative Radiology	11 Mar 2014	29
23	Systemic Exposure and Implications for Lung Deposition with an Extra-Fine Hydrofluoroalkane Beclometasone Dipropionate/Formoterol Fixed Combination Jean Bousquet, Gianluigi Poli, Daniela Acerbi et al. · Clinical Pharmacokinetics	Jun 2009	27
24	Mixed-Method Systematic Review and Meta-Analysis of Shared Decision-Making Tools for Cancer Screening Deborah Jael Herrera, Wessel van de Veerdonk, Neamin M. Berhe et al. · Cancers ReviewOpen access	29 Jul 2023	25
25	Recommendations on Isr in Multi Analyte Assays, Qa/Bioanalytical Consultants And Gcp By Global Cro Council For Bioanalysis (Gcc) Timothy Sangster et al. · Bioanalysis	Jul 2012	25
26	Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers Veit J. Erpenbeck, Eva Vets, Lien Gheyle et al. · Clinical Pharmacology in Drug Development Open access	8 Dec 2015	24
27	Similar Pharmacokinetics of the Adalimumab (Humira®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials Steven Ramael, Benjamin Van Hoorick, Renger G. Tiessen et al. · Rheumatology and Therapy Open access	29 Jun 2018	17
28	Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study Thomas G. Evans, Flora Castellino, Monika Kowalik Dobczyk et al. · The Lancet Microbe Open access	7 May 2024	14
29	2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION Avidan Uriel Neumann, Stéphanie Bibert, Bart L. Haagmans et al. · Journal of Hepatology Open access	Apr 2010	12
30	Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies Stephen H. Norris, Steven Ramael, Ippei Ikushima et al. · British Journal of Clinical Pharmacology Open access	23 Feb 2017	11
31	2012 VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION OF ACH-0141625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GENOTYPE-1 PATIENTS V. Detishin, Wouter Haazen, Heather Robison et al. · Journal of Hepatology Open access	Apr 2010	10
32	Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study Andrew D. Gewitz, Jeanne Mendell, Yuhuan Wang et al. · Clinical and Translational Science Open access	Apr 2024	8
33	LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial Christian Loesche, Damien Picard, Benjamin Van Hoorick et al. · Clinical and Translational Science Open access	Feb 2024	6
34	Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy Andreas Lindauer, Christian Laveille, Armel Stockis · Clinical Pharmacokinetics Open access	13 Mar 2017	6
35	P1‐221: Safety and pharmacokinetics of the novel BACE inhibitor MK‐8931 in healthy subjects following single‐ and Multiple‐Dose administration Jack Tseng, Marissa Fallon Dockendorf, Gopal Krishna et al. · Alzheimer s & Dementia	Jul 2012	6
36	Polyfluoroalkyl substances in dedicated hazardous waste incinerators: Framework and industrial scale experimental estimation of destruction and removal efficiency Jo Van Caneghem, Anneleen Verstegen, Geert Torremans et al. · Waste Management & Research The Journal for a Sustainable Circular Economy Open access	26 Jun 2025	5
37	Safety and Pharmacokinetics of MK ‐8527 in Adults Without HIV Gillian Gillespie, Russ P. Carstens, Xiaowei Zang et al. · Clinical and Translational Science Open access	Sep 2025	4
38	Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events Claudia S. Schmidt et al. · Human Vaccines & Immunotherapeutics Open access	May 2012	4
39	Systems Pharmacology: Enabling Multidimensional Therapeutics Stuart R. Maudsley, Hanne Leysen, Jaana van Gastel et al. · Elsevier eBooks Book chapter	30 Jan 2021	3
40	Why do healthy volunteers participate in clinical trials? Thijs van Iersel, Jelle Klein, Timothy Colin Hardman et al. · British Journal of Clinical Pharmacology	7 Mar 2026	2
41	Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans Jean‐Yves Gillon, François Simon, Sharan Sidhu et al. · Antimicrobial Agents and Chemotherapy Open access	22 Sep 2025	2
42	Healthy participant engagement in early clinical trials: results from the European EUFEMED survey Joshua P. Klein, Thijs van Iersel, Daniel H. de Vries et al. · Frontiers in Pharmacology Open access	Aug 2025	2
43	Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat) Dan Chalothorn et al. · Blood Open access	11 Jun 2026	1
44	Unexpected Clinical Drug-Drug Interaction of Fexinidazole on Midazolam Pharmacokinetics: Insights into Underlying Mechanisms from Clinical Phase I Study Results and Supporting In Vivo/Vitro Evidence Matthieu Gassiot, Priscilla Brun, Valérie Wauthier et al. · Clinical Drug Investigation Open access	18 Dec 2025	1
45	Elevated arsenic in topsoils developed on an iron-rich sedimentary formation: From multi-scale spatial patterns to human bioaccessibility Aubry Vandeuren, Benoît Pereira, Tanguy De Ryck et al. · Applied Geochemistry	4 Jul 2026	0
46	Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection Loukas Papargyris et al. · Nature Medicine Open access	Jul 2026	0
47	The possible institutionalisation of the carbon removal budget concept across the UNFCCC, UNCBD, and corporate net-zero strategies Jacopo Bencini, Laura Iozzelli · Environmental Science & Policy Open access	30 Apr 2026	0
48	Ethylated Phosphorylcholine as a New Marker for Alcohol Consumption: A Proof of Concept Catalina Dumitrascu, Elias Iturrospe, Els Scheir et al. · Drug Testing and Analysis	4 Aug 2025	0
49	Mass Balance, Pharmacokinetics, Metabolism and Excretion of Radiolabelled Acoziborole, a Potential Novel Treatment for Human African Trypanosomiasis, following Single Microtracer Oral Dose to Humans Jean‐Yves Gillon, François Simon, Sharan Sidhu et al. Preprint	16 Jun 2025	0
50	Ethylated phosphorylcholine – a new marker for ethanol consumption: A proof of concept Catalina Dumitrascu, Elias Iturrospe, Celine Gys et al. · Annales de Toxicologie Analytique	Mar 2025	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.